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Abstract
Human herpes viruses (HHVs) are widely distributed pathogens. In immuno-competent individuals their clinical outcomes
are generally benign but in immuno-compromised hosts, primary infection or extensive viral reactivation can lead to critical
diseases. Plasmodium falciparum malaria profoundly affects the host immune system. In this retrospective study, we
evaluated the direct effect of acute P. falciparum infection on reactivation and shedding of all known human herpes viruses
(HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-7, HHV-8). We monitored their presence by real time PCR in plasma and saliva of
Ugandan children with malaria at the day of admission to the hospital (day-0) and 14 days later (after treatment), or in
children with mild infections unrelated to malaria. For each child screened in this study, at least one type of HHV was
detected in the saliva. HHV-7 and HHV-6 were detected in more than 70% of the samples and CMV in approximately half.
HSV-1, HSV-2, VZV and HHV-8 were detected at lower frequency. During salivary shedding the highest mean viral load was
observed for HSV-1 followed by EBV, HHV-7, HHV-6, CMV and HHV-8. After anti-malarial treatment the salivary HSV-1 levels
were profoundly diminished or totally cleared. Similarly, four children with malaria had high levels of circulating EBV at day-
0, levels that were cleared after anti-malarial treatment confirming the association between P. falciparum infection and EBV
reactivation. This study shows that acute P. falciparum infection can contribute to EBV reactivation in the blood and HSV-1
reactivation in the oral cavity. Taken together our results call for further studies investigating the potential clinical
implications of HHVs reactivation in children suffering from malaria.
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Introduction
Human herpes viruses (HHVs) are widely distributed patho-
gens. Serological evidence of HHV infections are found in the
majority of the world’s population [1,2,3,4,5]. Following primary
infection, HHVs establish a long life persistent infection within the
human host characterized by frequent mild viral reactivation to
allow shedding and transmission. The latency tropism of select
HHVs is not yet fully characterized. In immuno-competent
individuals the clinical outcomes of HHVs are generally benign
whereas in immuno-compromised hosts primary infection or viral
reactivation can lead to critical diseases such as encephalitis [6],
meningitis [7], pneumonitis [8] and to the emergence of malignant
disorders [5,9,10,11]. These facts reflect a delicate equilibrium
between viral lytic replication and host immune responses. If this
balance is upset, failure to restrain the viral load can lead to severe
pathogenesis.
Saliva appears to be an important compartment for transmis-
sion of several HHVs and it is likely that both the amount and
frequency of HHVs in saliva are determinants of risk for
transmission [12]. Herpes simplex virus 1 and 2 (HSV-1, HSV-
2), varicella-zoster virus (VZV), Epstein-Barr virus (EBV),
cytomegalovirus (CMV), and human herpesvirus 6, 7 and 8
(HHV-6, HHV-7, HHV-8) belong to the Herpesviridae family
commonly infecting people and can be classified in three different
sub-families sharing genetic and biological similarities (a, b and c
herpesviridae). In affluent countries primary infections by b herpes
viruses (CMV, HHV-6, and HHV-7) occur very early in
childhood [13,14] while primary infections by a viruses (HSV-1,
HSV-2, VZV) and c viruses (EBV and HHV-8) are usually
delayed until the young adult life. In Sub-Saharan Africa, where
malaria is holo-endemic, HHVs primary infections occur earlier in
life and herpes viruses are widespread among young children.
The impact of acute malaria infection on HHV reactivation and
shedding has not been fully characterized. If a viruses are
neurotropic, b and c viruses can establish latency in certain types
of peripheral blood mononuclear cells (PBMCs) and/or in vascular
endothelial cells. [15,16,17]. Our previous studies indicate that
malaria affects EBV persistence as reflected by an increased viral
replication. Children living in malaria-endemic areas have
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infection leads to increased levels of circulating EBV that are
cleared following anti-malaria treatment [20]. Furthermore, we
demonstrated that a malarial antigen was able to directly drive an
infected B cell into EBV lytic replication [21]. Increased
reactivation of the oncogenic EBV could lead to an augmented
risk of developing malignancies [22]. Acute P. falciparum malaria
infection has also been suggested to induce HSV-1 and VZV
reactivation [23,24,25]. To extend our previous studies and
evaluate the direct effect of acute malaria infection on reactivation
and shedding of a wider range of HHVs, we analysed the viral
DNA load of HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-
7 and HHV-8 in plasma and saliva from children with acute
malaria and 14 days after they received anti-malarial treatment.
Materials and Methods
Patients
This retrospective study was carried out on samples collected in
Kampala, Uganda from October to December, after the second
rainy season 2002. Children with malaria and children with mild
infections unrelated to malaria were recruited at the Assessment
Center, Mulago National Referral Hospital, Kampala, Uganda.
Plasma and saliva were collected from children with acute
uncomplicated malaria (M
+) on the day of recruitment (M
+ day-
0, n=23), from the same children 2 weeks after they had received
anti-malaria treatment (M
+ day-14; n=23; age range 2–15 years;
mean age 6,6 years) and from children with mild infections
unrelated to malaria (M
2; n=24; age range 2–14 years; mean age
6,8 years). Children admitted to the hospital and presenting P.
falciparum parasitemia (parasites were detected in their blood
smears) were classified in the acute malaria group. At enrolment,
M
+ children received anti-malaria treatment consisting of
sulfadoxine (25 mg/kg) and pyrimethamine (1.25 mg/kg) (Fansi-
dar; Roche) on day-0 plus amodiaquine (Camoquine; Park-Davis)
(25 mg/kg in 3 divided doses) on days 0, 1, and 2. Some children
received paracetamol and/or an anticough mixture. The M
2
control group consisted of children who visited the clinic with a
variety of symptoms unrelated to malaria (no parasites were
detected in their blood smears). The study protocols were
approved by the ethics committees of Makerere University Faculty
of Medicine, the Uganda National Council of Science and
Technology, and the Karolinska Institutet. Written, informed
consent was obtained from guardians of study participants.
Detailed clinical data of the patients are presented in Table S1.
Blood and saliva samples
Venous blood (2–5 mL) was collected in tubes containing
EDTA and was centrifuged to obtain the plasma fraction. Saliva
was obtained by the following method: children chewed a sponge
for 1 min, the sponge was then washed in 1 mL of PBS. All
samples were stored at 220uC until further processing.
Viral DNA quantification
DNA extraction from plasma and saliva samples was performed
using a fully automated workstation (BioRobotH M48; Qiagen,
MagAttractH DNA Mini M48 Kit; Qiagen) to insure maximum
reliability. Following manufacturer’s instructions, DNA was
extracted from 200 mL of samples (plasma or saliva) and eluted
in 200 mL DNAse free water.
Viral DNA quantification of HSV-1, HSV-2, VZV, EBV,
CMV, HHV-6, HHV-7 and HHV-8 was assessed by real time
polymerase chain reaction (PCR) according to optimized protocols
[26] approved and used for routine diagnostics at the Swedish
Institute for Communicable Disease Control, Solna, Sweden. The
PCR was carried out in 96-well plates in a final volume of 25 mL
including 5 mL of DNA sample. Briefly, the PCR mixture consisted
of 12,5 mL of TaqManuniversalPCRmix(Applied Biosystems)and
various amounts and concentrations of MgCl2, water, primers and
fluorescence-labelled probes. Cycling parameters were 50uC for
2 min, 95uC for 10 min, 45 cycles 95uC for 15 s, and 60uC for
1 min. Detection was performed using an ABI Prism 7900
Sequence Detection System (Applied Biosystems). Data were
analyzed with SDS2.3 software (Applied Biosystems) in reference
to a standard curve prepared using serial dilutions of DNA derived
from the EBV-positive BL line Namalwa that contains two copies of
EBV genome per cell. The sensitivity of the assay (detection limit)
was 1–5 viral copies per reaction well. As positive control, DNA of a
select HHV (50-100 copies/mL) was added to the assay to ensure
PCR reliability. The DNA copy number for each virus was
calculated as the mean value of triplicates.
Statistical analysis
Given the small sample size, statistical analyses were performed
using non-parametric statistical tests. Wilcoxon Signed-Ranks Test
for paired analysis and Mann-Whitney Rank-Sum Test for group
comparison were used. P,0.05 was considered to be statistically
significant.
Results
We determined the prevalence (detection rate) and loads of
HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-7 and HHV-8
regardless of the patient HHVs serological status in plasma and
saliva samples from children having acute P. falciparum infection at
the date of admission at the hospital (M
+ day-0), 14 days after anti-
malarial treatment (M
+ day-14). The M
- group, composed of
Ugandan children that are age-, sex-matched and of same ethnical
and geographical origins to the M
+ group is used to ascertain that
any effect on viral reactivation and/or shedding observed within
the M
+ group between day-0 and day-14 would most exclusively
result from malaria infection and not from other types of illness.
Prevalence of HHVs in saliva and plasma
For each child screened in this study, at least one type of HHV
was detected in the saliva. [Table S2]. The order of prevalence of
the tested viruses was the same in the salivary samples from M
+ at
day-0 and at day-14. HHV-7, EBV and HHV-6 were detected in
more than two third of the samples, CMV in almost half of the
samples. HSV-1, HHV-8, and VZV were detected at lower
frequency. It is noticeable that the proportion of saliva samples
with detectable HSV-1 was much lower after anti-malaria
treatment (30% at day-0 and 13% at day-14) [Figure 1] even
though this difference was not statistically significant due to the
limited number of samples.
The HHVs detection rate was lower in the plasma that in the
saliva samples. Forty two per cent (5/12) of the plasma samples M
+
day-0 and 8% (1/12) of the plasma samples from the M
+ day-14
had detectable viral DNA levels of at least one HHV. At day-0 the
most prevalent virus in the plasma was EBV (33%) followed by
HSV-1 and VZV (8%) while at day-14 only 8% (1/12) of the
samples had detectable EBV.
In the M
2 group, only one child had detectable HHV in the
plasma (patient 36 positive for CMV). Salivary HHVs prevalence
was as follow; HHV-7 (96%), HHV-6 (75%), EBV (63%), CMV
(50%), HSV-1 (17%), HHV-8 (8%), VZV (0%) and HSV-2 (0%).
HSV-2 was not detected in any of the samples regardless the
group or the physiological compartment tested.
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a herpes viruses. Paired analysis of HSV-1 levels for each
patient between day-0 and day-14 showed a profound reduction of
HSV-1 levels in the saliva after anti-malarial treatment (Wilcoxon
Signed-Ranks Test; P=0.016) [Figure 2]. One child (1/12) had
detectable HSV-1 in both the plasma (2.9610
3 copies/mL) and
the saliva (3.4610
7 copies/mL) at day-0. HSV-1 was not detected
in the plasma of the same patient after anti-malarial treatment
while the HSV-1 viral load in the saliva was profoundly reduced
(2.7610
4 copies/mL). Group comparison using the Mann-Whitley
Rank-Sum Test between M
+ day-0 and M
2 saliva samples showed
that the respective levels of HSV-1 were not significantly different
(P=0.289). HSV-1 was not detectable in any of the M
2 plasma
samples.
HSV-2 was not detectable in any of the samples of the M
+ or
M
2 groups whereas one patient had detectable levels of VZV in
the saliva (3.4610
4 copies/mL) and in the plasma (3.6610
3
copies/mL) at day-0. VZV was cleared from the saliva and the
plasma after the patient received anti-malarial treatment. VZV
was not detectable in any of the M
2 samples.
b herpes viruses. Paired analysis of CMV levels for each
patient between day-0 and day-14 showed that the respective
levels of CMV in the saliva were not significantly affected
(Wilcoxon Signed-Ranks Test; P=0.424) [Figure 2]. CMV was
not detectable in any of the plasma samples M
+. The mean
salivary CMV load in the M
2 group was 4.1610
4 copies/mL.
Group comparison using the Mann-Whitley Rank-Sum Test
between M
+ day-0 and M
2 saliva samples showed that the
respective levels of CMV were not significantly different
(P=0.407). Only one plasma sample (1/12) had a detectable
level of CMV (4.4610
3 copies/mL).
Paired analysis of HHV-6 levels for each patient between day-0
and day-14 showed that the respective levels of HHV-6 in the
saliva were not significantly affected (Wilcoxon Signed-Ranks
Test; P=0.953). HHV-6 was not detectable in any of the plasma
samples of the M
+ or M
2 groups. Group comparison using the
Mann-Whitley Rank-Sum Test between M
+ day-0 and M
- saliva
samples showed that the respective levels of HHV-6 were not
significantly different (P=0.519).
Paired analysis of HHV-7 levels for each patient between day-0
and day-14 showed that the respective levels of HHV-7 in the
saliva were not significantly affected (Wilcoxon Signed-Ranks
Test; P=0.270). HHV-7 was not detectable in any of the plasma
samples of the M
+ or M
2 groups. Group comparison using the
Mann-Whitley Rank-Sum Test between M
+ day-0 and M
- saliva
samples showed that the respective levels of HHV-7 were not
significantly different (P=0.327).
c herpes viruses. Paired analysis of EBV levels for each
patient between day-0 and day-14 showed that the respective
levels of EBV in the saliva were not significantly affected
(Wilcoxon Signed-Ranks Test; P=0.211) [Figure 2]. Four plasma
samples (4/12) showed detectable levels of EBV (mean 4.5610
4
copies/mL) at day-0. After anti-malarial, EBV was no longer
detectable in 3 of these patients and had dropped from 4610
5
copies/mL to 1610
4 copies/mL for the fourth one. Due to the
small number of samples this trend is not statistically significant
(Wilcoxon Signed-Ranks Test; P=0.125) but is in line with
previously published results performed at a larger scale [20].
Group comparison using the Mann-Whitley Rank-Sum Test
between M
+ day-0 and M
- salivary samples showed that the
respective levels of EBV were not significantly different
(P=0.575). EBV was not detectable in any of the M
2 plasma
samples.
HHV8 was detected in only two salivary samples from each
group.
HHVs loads in saliva during viral shedding
In order to assess the HHVs loads in saliva during shedding
among the 3 groups we determined the mean viral DNA copy
numbers in salivary samples for each herpes virus. Only samples
with detectable viral DNA, reflecting viral shedding, were
considered for this analysis [Table S2].
a herpes viruses. Group comparison showed a profound
reduction of HSV-1 DNA levels in the saliva after anti-malarial
treatment (Mann-Whitney Rank-Sum Test; P=0.017) [Figure 3].
The mean HSV-1 load in the saliva samples from the M- group
(5.5610
7 copies/mL) was similar to the mean viral load in the M
+
day-0 saliva samples. No viral DNA was detectable in any of the
saliva samples for HSV-2 and only one patient (1/23) had
detectable VZV in the saliva at day-0 (3.4610
4 copies/mL).
b herpes viruses. Group comparison of each viral load using
the Mann-Whitney Rank-Sum Test between M
+ day-0, M
+ day-
14 and M
2 saliva samples showed that the respective levels of b
herpes viruses were not significantly different [Figure 3].
c herpes viruses. Group comparison of EBV loads using the
Mann-Whitney Rank-Sum Test between M
+ day-0, M
+ day-14
and M
2 saliva samples showed that the respective levels of EBV
were not significantly different [Figure 3]. Despite the few
Figure 1. Prevalence of HHVs in saliva and plasma. Detection rate of HHVs in saliva samples and plasma samples from children with acute
malaria before (M
+ day-0; light gray bars) and after (M
+ day-14; dark gray bars) anti-malarial treatment and in children having mild infections
unrelated to malaria (M
2; black bars). All samples were considered for this analysis, regardless the serological status of the patients for a select HHV.
doi:10.1371/journal.pone.0026266.g001
Malaria Infection and Herpes Viruses Reactivation
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26266Figure 2. HHVs loads in saliva and plasma before and after anti-malarial treatment. HHVs loads (viral DNA copies/mL) in saliva and plasma
samples from children with acute malaria before (day-0) and after (day-14) anti-malarial treatment and in children having mild infections unrelatedt o
malaria (M
2). Each black circle represents the viral load for a select HHV for one patient. The black continuous lines link the viral loads of a select HHV
at day-0 and at day-14 for the same patient. Paired analysis between the M
+ day-0 and M
+ day-14 samples were performed using the Wilcoxon
Signed-Ranks Test. P,0.05 was considered to be statistically significant. The dashed horizontal lines represent the mean viral load for a select HHV in
each group. All samples with less than 200 viral DNA copies/mL were considered negative.
doi:10.1371/journal.pone.0026266.g002
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group), the calculated means of salivary HHV-8 copies in saliva
samples M
+ day-0, M
+ day-14 and M
- were respectively 3.9610
3,
3.4610
3 and 2.9610
4 copies/mL.
During salivary shedding in the M
+ day-0 and M
2 groups, the
highest mean viral load was observed for HSV-1 followed by EBV,
HHV-7, HHV-6, CMV and HHV-8. In the M
+ day-14 group
there was a drastic reduction of HSV-1 levels in the saliva, the
highest salivary viral load being observed for EBV followed by
HHV-7, HHV-6, CMV, HHV-8 and HSV-1. In the 3 groups,
linear regression analysis could establish a correlation between b
herpes virus DNA levels during salivary shedding and prevalence
of virus detection in the saliva (M
+ day-0, R=0.99; M+ day-14,
R=0.95; M-, R=095). During shedding, an increased viral load
for a select b herpes virus was correlated to a higher detection rate
[Figure 4]. The efficiency of b herpes viruses transmission within a
population is most likely directly proportional to the number of
viral particles present in the saliva during shedding confirming that
saliva is a privileged route of transmission for CMV, HHV-6 and
HHV-7.
Discussion
HHVs infections are usually benign in immuno-competent
individuals. Nevertheless, extensive viral reactivation under certain
conditions such as immuno-suppression can lead to severe illness.
Detection of herpes virus in plasma of patients with AIDS or after
stem cell transplantation has been widely reported [27,28].
Monitoring herpes viruses activity by viral quantification in
plasma or saliva samples can serve as a useful diagnostic tool for
viral associated diseases [29,30].
P. falciparum malaria profoundly affects the host immune system
by mediating at the same time immuno-suppression and immune
hyper-activation. This is reflected by the impairment of macro-
phage function and antigen presentation (dendritic cell inhibition),
by a diminished specific T-cell response and the induction of
regulatory T cells. Polyclonal B cell activation leads to hyper-
gamma-immunoglobulinemia and production of auto-antibodies.
P. falciparum infection is also accompanied by high plasma levels of
pro-inflammatory cytokines (IL-6, TNFa) and regulatory cytokines
(IL-10, TGFb) [31]. This immunological state could be envisaged
Figure 3. Salivary shedding of HHVs before and after anti-malarial treatment. Quantitative comparison of HHVs loads (viral DNA copies/
mL) during salivary shedding in children with acute malaria before (M
+ day-0; light gray circles) and after (M
+ day-14; dark gray circles) anti-malarial
treatment and in children having mild infections unrelated to malaria (M
2; black circles). Each white circle represents the viral load for a select HHV
for one patient. White squares depict the mean values, with standard deviations. For a select HHV, only samples with detectable viral DNA, reflecting
salivary shedding, were considered for this analysis (n=number of samples analyzed).
doi:10.1371/journal.pone.0026266.g003
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Furthermore, direct contacts between malarial antigens and
latently infected cells may also result in viral reactivation as we
have previously described for a PfEMP1-CIDR1a variant that is
able to drive an EBV latently infected B cell into lytic replication
[21]. In this report, we have screened all known human herpes
viruses in plasma and saliva samples from children with acute
uncomplicated P. falciparum infection and followed up the same
patients 14 days after anti-malarial treatment.
Neurotropic a herpes viruses (HSV-1, HSV-2, VZV) establish
latent infection mainly in the trigeminal and dorsal root ganglia
maintaining the potential to resume viral replication to insure
shedding and transmission. In immuno-competent individuals,
VZV reactivation occurs mainly once in the lifetime while it is
recurrent for HSV-1 and HSV-2 generally associated with mild to
moderate illness. Our results show that some children having acute
P. falciparum carry high levels of HSV-1 in the saliva. After anti-
malarial treatment the salivary HSV-1 levels were profoundly
diminished and totally cleared in 5 out of 7 positive children. In
the M
+ group, one plasma sample had detectable of HSV-1 at day-
0, the virus been cleared at day-14. The results are in line with
previous studies associating clinical manifestations of herpes
labialis (HSV-1) to acute P. falciparum in children [23]. A variety
of factors such as stress and fever have been shown to be able to
induce reactivation of herpes simplex viruses. HSV-1 was also
detected in the saliva samples from the malaria negative study
group. In the M- group HSV-1 reactivation in the oral cavity
could be attributed to the fact that these patients have mild
infections, active ongoing immune response and associated fever
(Table S1). Nevertheless, the detection rate of HSV-1 in the saliva
samples from the M
+ day-0 group (7/23) was almost double that of
the M
2 group (4/24). The observed decrease in HSV-1 levels in
the saliva between day-0 and day-14 is unlikely to result from a
potential antiviral property of the treatment since the salivary
levels of the other HHVs were not affected.
HSV-2, thought to be mainly sexually transmitted, was not
detected in any of the children assessed. One child with acute
malaria had noticeable VZV in the saliva and in the plasma the
day of admission to the hospital. After anti-malaria treatment
VZV was no longer detectable either in the saliva or in the plasma
and a number of case reports indicate that herpes zoster
reactivation can occur during P. falciparum [24,25,32].
Reactivation of a herpes viruses can lead to severe neurological
disorders such as herpes simplex encephalitis (HSE) or acute
disseminated encephalomyelitis (ADEM) [6,7,32]. The data
presented here together with previous reports on reactivation of
a herpes viruses in malaria, call for studies investigating if a herpes
viruses may contribute to neurological complications, commonly
diagnosed as cerebral malaria, during P. falciparum infection. Saliva
appears to be a relevant compartment to assess a herpes viruses
reactivation. Furthermore, measuring HSV loads in the saliva
rather that in the plasma could present substantial advantages for
routine screenings since this compartment is more accessible.
Nevertheless, even if monitoring neurotropic viruses in other
compartments, like the cerebrospinal fluids, might also be of
interest access to such samples could prove difficult.
Beta herpes viruses (CMV, HHV-6 and HHV-7) can establish
latent infections in peripheral mononuclear cells (PBMCs) [16,17]
and can be reactivated in immuno-suppressed individuals and lead
to clinical symptoms [27,33]. P. falciparum infected erythrocytes
have been reported to directly interact with a variety of PBMCs
such as monocytes/macrophages, platelets, granulocytes [34],
dendritic cells [35] and B cells [36]. It was thus of interest to
investigate if these interactions could lead to viral reactivation.
Moreover, HHV-6 and HHV-7 are considered to be causative
agents of exanthema subitum that can lead to febrile seizures.
Several reports also suggest that HHV-6 and HHV-7 can invade
the central nervous system and lead to severe neurological
manifestations [37,38,39]. In our study, we observed no significant
change in b herpes viral load between the M
+ day-0, M
+ day-14
and the M
- saliva samples. Beta herpes viruses were not detected in
any of the plasma samples from the M
+ groups.
The association between malaria and EBV reactivation has
already been established and the data has been thoroughly
discussed elsewhere [18,20,22]. HHV-8 belongs to the same c
herpes virus sub-family as EBV, sharing genetic and biological
similarities. As EBV, HHV-8 can establish latency in B cells and is
also linked to malignancies. [10]. These similarities with EBV
make assessment of HHV-8 reactivation interesting in malaria
patients. Moreover, epidemiological studies from Italy revealed a
drop in HHV-8 sero-prevalence over time coinciding with the
drop of malaria vectors in the same geographical setting [40,41].
In the samples assessed here, the incidence of HHV-8 was too low
to draw any conclusions since only 2/23 patients in each group
had detectable HHV-8 in the saliva.
We conclude from our study that acute P falciparum infections
can contribute to EBV reactivation in the blood and HSV-1
reactivation in the oral cavity. Acute malaria was not associated
with reactivation of the b herpes viruses CMV, HHV-6 and HHV-
7 and the sample size in this study was too small to draw any
conclusions on the impact of malaria on VZV and HHV-8
reactivation. A prospective study including a larger number of
individuals would be required. The age group examined was
probably too young for assessment of HSV-2 reactivation. Taken
Figure 4. b herpes viruses prevalence and shedding. Correlation established by linear regression analysis between b herpes viruses loads
during salivary shedding (data from Figure 3) and b herpes viruses prevalence (detection rate) in all the saliva sample analyzed. (M
+ day-0; light gray
circles), (M
+ day-14; dark gray circles), (M
2; black circles).
doi:10.1371/journal.pone.0026266.g004
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potential clinical implications of HHVs reactivation in children
suffering from malaria.
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(viral DNA copies/mL) in plasma samples (P) and saliva (S) from
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